VYNE Therapeutics Inc (VYNE)

$VYNE 90 DAYS STOCK PRICE FORECAST

Stock Price

About the Company

VYNE's mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.

Exchange

NASDAQ

Website

vynetherapeutics.com

$16M

Total Revenue

106

Employees

$51M

Market Capitalization

2.31

Price/Earning ratio

Similar Companies

Name Ticker Market Capitalization (USD M) Revenue (USD M) Price/Book Price/Earning Net Margin (%)
Conversion Labs Inc CVLB 108548 35213 3.74 42.66 7.33
Royalty Pharma plc RPRX 18925 2239 2.81 15.20 43.40
Organon & Co. OGN 8844 7891 -4.56 5.07 22.06
Arvinas Inc ARVN 3725 21 7.48 -22.56 -782.93
Tilray Inc TLRY 3241 564 1.08 -8.14 -66.49
ATAI Life Sciences N.V. ATAI 2272 20 4.78 -10.40 -932.88
Usana Health Sciences Inc USNA 2079 1254 4.73 14.98 11.09
Cronos Group Inc CRON 1935 57 1.22 -13.40 -258.59
NRX Pharmaceuticals Inc NRXP 1170 2321 0.45 5.05 9.91
Phathom Pharmaceuticals Inc PHAT 964 6.54 -6.01 None
Intersect ENT Inc XENT 893 103 21.65 -13.01 -66.55
Phibro Animal Health Corp. PAHC 893 833 3.70 16.25 6.53
Edgewise Therapeutics Inc EWTX 796 2.70 -29.55 None
Fulcrum Therapeutics Inc FULC 711 15 8.62 -9.63 -481.07
Pliant Therapeutics Inc PLRX 614 13 2.51 -7.16 -613.56
Cyteir Therapeutics Inc CYT 596 3.20 -20.62 None
Urovant Sciences Ltd UROV 503 -3.65 -3.08 None
Ikena Oncology Inc IKNA 404 10 2.18 -7.38 -551.28
Chromadex Corp CDXC 394 62 9.92 -16.62 -37.51
Provention Bio Inc PRVB 377 2.53 -2.94 None
Rain Therapeutics Inc RAIN 355 413 2.19 -11.66 123.20
Verrica Pharmaceuticals Inc VRCA 325 12 6.58 -8.94 -301.45
Evolus Inc EOLS 310 77 4.10 -2.08 -171.53
Terns Pharmaceuticals Inc TERN 252 1.40 -7.30 None
Adicet Bio Inc ACET 251 9 1.09 -4.46 -603.06
Milestone Pharmaceuticals Inc MIST 219 15 1.23 -7.37 -215.93
Kaleido Biosciences Inc KLDO 184 1 4.11 -2.07 None
Citius Pharmaceuticals Inc CTXR 179 2.24 -7.81 None
scPharmaceuticals Inc SCPH 167 119 2.45 -5.52 -27.05
Eyenovia Inc EYEN 143 6 16.29 -7.31 -324.94
Aquestive Therapeutics Inc AQST 142 42 -2.95 -2.21 -152.73
LifeMD Inc LFMD 139 64 -22.39 -1.00 -133.55
Eton Pharmaceuticals Inc ETON 124 15 6.13 -10.10 -74.52
Osmotica Pharmaceuticals Plc OSMT 122 190 2.37 -1.31 -47.85
Kala Pharmaceuticals Inc KALA 119 11 1.53 -0.94 None
Xeris Biopharma Holdings Inc XERS 111 34 12.19 -1.44 -248.46
Odonate Therapeutics Inc ODT 110 1.39 -0.94 None
Anebulo Pharmaceuticals Inc ANEB 101 7.83 -2.54 None
Opiant Pharmaceuticals Inc OPNT 100 37 3.03 -96.15 -3.06
Aerpio Pharmaceuticals Inc ARPO 99 15 2.98 -5.24 -28.77
Mannatech Inc MTEX 82 158 3.27 12.89 4.22
Natural Alternatives Internati NAII 80 179 1.07 7.90 6.03
India Globalization Capital In IGC 67 0 2.45 -7.60 -981.18
VYNE Therapeutics Inc VYNE 51 16 0.77 2.31 -554.66
Shineco Inc TYHT 44 3 2.17 -1.55 -159.60
Assertio Holdings Inc ASRT 36 117 0.49 -0.63 -38.05
Dermata Therapeutics Inc DRMA 36 -75.67 -7.32 None
Acasti Pharma Inc ACST 33 0 1.43 -1.66 -611.47
Nabriva Therapeutics Plc NBRV 29 12 0.88 -0.49 -452.55
Lexaria Bioscience Corp LEXX 27 1 3.76 -6.95 -445.15
Bio-Path Holdings Inc BPTH 26 0 1.19 -2.49 18.96
Reviva Pharmaceuticals Holding RVPH 25 1.41 -4.08 None
Baudax Bio Inc BXRX 25 1 -10.80 0.76 9.10
Trevi Therapeutics Inc TRVI 23 1.64 -0.66 None
Timber Pharmaceuticals Inc TMBR 20 0 8.75 0.67 -527.55
Hoth Therapeutics Inc HOTH 19 1.64 -2.02 None
Cyanotech Corp. CYAN 17 34 0.99 13.57 3.83
Sonoma Pharmaceuticals Inc. SNOA 11 17 3.32 -2.16 -31.96

Why Should VYNE Therapeutics Inc. (VYNE) Be In Your Portfolio?

17h ago, source: marketingsentinel

VYNE Therapeutics Inc. (NASDAQ:VYNE) has a beta value of 0.70 and has seen 2.11 million shares traded in the last trading ...

VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

21h ago, source: YAHOO!Finance

Important milestone achieved as part of the Company’s new corporate strategy to develop treatments for immuno-inflammatory diseases Topline results anticipated in early Q1 2022 BRIDGEWATER, N.J., Oct.

VYNE Therapeutics Inc. (NASDAQ: VYNE): Don’t Ditch VYNE Stock In 2021

13d ago, source: marketingsentinel

In the last trading session, 1.02 million VYNE Therapeutics Inc. (NASDAQ:VYNE) shares changed hands as the company’s beta touched 0.71. With the company’s per share price at $1.19 changed hands at -$0 ...

Looking Closely at the Growth Curve for VYNE Therapeutics Inc. (VYNE)

13d ago, source: newsheater

VYNE Therapeutics Inc. (NASDAQ:VYNE) went down by -5.56% from its latest closing price compared to the recent 1-year high of $13.20. The company’s stock price has collected -20.13% of loss in the last ...

VYNE Therapeutics Inc.(VYNE)

12d ago, source: The Motley Fool

The environmental score is comprised of weighted key performance indicators related to natural capital, innovation, and climate change. The social score is comprised of weighted key performance ...

VYNE Therapeutics (NASDAQ:VYNE) Upgraded by Zacks Investment Research to Buy

4d ago, source: Stock Market Daily

VYNE Therapeutics stock has undergone multiple analysts rating changes in the recent past.  VYNE Therapeutics Upgraded by ...

VYNE Therapeutics Announces its China Partner's Enrollment of First Patient in Phase 3 Study of AMZEEQ® in Patients with Moderate to Severe Acne

12d ago, source: Stockhouse

BRIDGEWATER, N.J., Oct. 05, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the first patient ...

Satsuma Pharmaceuticals Announces the Appointment of Mutya Harsch to its Board of Directors

7d ago, source: Middle East North Africa Financial Network

Prior to joining VYNE Therapeutics in March 2020 ... and financial performance and condition of Satsuma Pharmaceuticals, Inc. (the“Company”), as well as the Company's plans, objectives ...

VYNE Therapeutics Inc VYNE

6d ago, source: Morningstar%2c Inc.

There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible ...

Satsuma Pharmaceuticals Announces the Appointment of Mutya Harsch to its Board of Directors

7d ago, source: Yahoo Finance

Prior to joining VYNE Therapeutics in March 2020 ... operations and financial performance and condition of Satsuma Pharmaceuticals, Inc. (the “Company”), as well as the Company’s plans, objectives and ...

VYNE Therapeutics Inc VYNE

5d ago, source: Morningstar%2c Inc.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Satsuma Pharmaceuticals Announces the Appointment of Mutya Harsch to its Board of Directors

7d ago, source: Stockhouse

CloseCurlyDoubleQuote; Prior to joining VYNE Therapeutics in March 2020 ... operations and financial performance and condition of Satsuma Pharmaceuticals, Inc. (the “Company”), ...

Your Portfolio